A snarl of regulators influence cardiac hypertrophy, but factors that negatively regulate this process are not well understood. A new molecule has now emerged that seems to control pathologic but not physiologic cardiac hypertrophy in mice. It works by repressing the activity of a key transcription factor after both molecules are induced (pages 837–844).
